title: Evolution: IMiDs to PPMs, revolution in DLBCL?
abstract: In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of diffuse large B-cell lymphoma (DLBCL).
authors.affiliation: MAYO CLINIC.
authors.forename: Grzegorz S
authors.identifier: http://orcid.org/0000-0002-6955-9393
authors.initials: GS
authors.lastname: Nowakowski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects*; D006801:Humans; D051740:Ikaros Transcription Factor / Q000235:genetics*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D010447:Peptide Hydrolases / Q000235:genetics*; D010881:Piperidones / Q000494:pharmacology*; D052999:Quinazolinones / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D010881:Piperidones; D052999:Quinazolinones; D051740:Ikaros Transcription Factor; D010447:Peptide Hydrolases